Chief Financial Officer · Cartesian Therapeutics, Inc. (RNAC)

Blaine Davis

A named executive officer of Cartesian Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,949,927

Salary $475,860Stock awards $372,460

FY2024: $3,971,412

4th of 5 named executive officers at Cartesian Therapeutics by FY2025 total.

5 named officers on file for Cartesian Therapeutics, FY2025

Blaine Davis’s pay file — $29

  • 4 fiscal years of pay, line by line
  • RNAC’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cartesian Therapeutics’s whole pay program stands against its peers

  • Cartesian Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RNAC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Free

Get Blaine Davis’s full pay file as a PDF — free

More than this page: up to 10 years of Blaine’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Blaine Davis compensation by year

Cartesian Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Cartesian Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024FY2025
Salary$33,846$440,000$462,000$475,860
Bonus$0$880,000$0$0
Stock awards$0$0$1,599,840$372,460
Option awards$1,228,750$0$1,634,460$884,122
Non-equity incentive$0$176,000$240,240$205,572
Pension and deferred compensation$0$0$0$0
All other$1,110$998,759$34,872$11,913
Total$1,263,706$2,494,759$3,971,412$1,949,927

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cartesian Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001453687-26-000072, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cartesian Therapeutics, Inc. filed document, accession 0001453687-26-000072. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.

$1.3M
$2.5M
$4.0M
$1.9M
FY22
FY23
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU60,600$436,926—
RSU22,000$158,620—
Option77,749—$19.66
Option64,600—$16.93

Per the Outstanding Equity Awards at Fiscal Year-End table in Cartesian Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Cartesian Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Carsten BrunnPresident and Chief Executive Officer$4,329,868
Metin KurtogluFormer Chief Technology Officer$2,474,034
Christopher JewellFormer Chief Scientific Officer$2,015,707
Blaine Davis · this pageChief Financial Officer$1,949,927
Milos MiljkovicChief Medical Officer$1,657,535

The full Cartesian Therapeutics compensation record

free company brief

This page is one person within Cartesian Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Cartesian Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cartesian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Blaine Davis's compensation dossier · One-time report. No refunds.